ArticleArchives of medical science : AMS2010
Is there any correlation between TNF-related apoptosis-inducing ligand (TRAIL) genetic variants and breast cancer?
Article in Archives of medical science : AMS, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- Enhanced apoptotic activity in allergic diseases and its relationship with eosinophil cationic protein, systemic inflammation, and severity of atopic sensitisation.Archives of medical science : AMS · 2025Article
- TRAIL C1595T Variant Critically Alters the Level of sTRAIL in Terms of Histopathological Parameters in Colorectal Cancer.Indian journal of clinical biochemistry : IJCB · 2024Article
- Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer.The Libyan journal of medicine · 2019Article
- Association between breast cancer and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) gene 1595C/T SNP in a Pakistani population.Contemporary oncology (Poznan, Poland) · 2016Article
- Association between TRAIL gene polymorphisms and the susceptibility and severity of lumbar disc degeneration.International journal of clinical and experimental pathology · 2015Article
- Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.International journal of chronic obstructive pulmonary disease · 2015Article
- Tumor necrosis factor inhibitors - state of knowledge.Archives of medical science : AMS · 2014Article
- Article
- Pathological complete response in younger and older breast cancer patients.Archives of medical science : AMS · 2012Article
- Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to omalizumab treatment.Medical science monitor : international medical journal of experimental and clinical research · 2012Article
- Association between polymorphisms of XRCC1, p53 and MDR1 genes, the expression of their protein products and prognostic significance in human breast cancer.Medical science monitor : international medical journal of experimental and clinical research · 2011Article
- Erythropoietin update 2011.Medical science monitor : international medical journal of experimental and clinical research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTNF-related apoptosis-inducing ligand (TRAIL) is a death ligand and also a member of the TNF superfamily. We aimed to investigate the possible relationship between TRAIL and breast cancer. Here, we report the results of the first association study on genetic variation in the TRAIL gene and its effect on breast cancer susceptibility and prognosis. MATERIAL AND
methodsA C/T polymorphism at 1595 position in exon 5 of the TRAIL gene was genotyped in a Turkish breast cancer case-control population including 53 cases (mean age: 55.09 ±11.63 years) and 57 controls (mean age: 57.17 ±17.48 years) using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.
resultsThere were no differences in the distribution of TRAIL genotypes and frequencies of the alleles in the breast cancer patients and controls. A heterozygous TRAIL CT polymorphism in exon 5 was present in 8.3% of tumour stage III-IV and 48.8% of stage I-II patients, and in 42.1% of controls. The reduced frequency of this genotype in patients who had advanced tumour stage was statistically significant (p = 0.017).
conclusionsOur findings indicate that genetic variants of TRAIL at position 1595 in exon 5 might be associated with progression of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.